ALBAWABA The Food and Drug Administration (FDA) has achieved a significant milestone in women's mental health by approving the first oral treatment for postpartum depression. This groundbreaking drug, called zuranolone, will be marketed as Zurzuvae by Sage Therapeutics and Biogen, offering hope to the estimated 15% of women who experience postpartum depression in the weeks or months following childbirth. Postpartum depression is a form of major depression that can develop ...